ZAIVALIFESCIENCES
Gabalex-AT pharmaceutical pack by Zaiva Lifesciences

Neurology & Neuropathic Pain

Gabalex-AT

Gabapentin + Amitriptyline · 300 mg + 10 mg

A dual-mechanism combination targeting peripheral neuronal excitability and descending pain modulation.

BrandGabalex-AT
CompositionGabapentin + Amitriptyline
Strength300 mg + 10 mg
Dosage formTablet

Overview

Neuropathic pain where gabapentin plus low-dose amitriptyline is clinically appropriate.

  • Gabapentin binds the α2δ subunit of voltage-gated calcium channels and reduces excitatory neurotransmitter release.
  • Amitriptyline inhibits serotonin and noradrenaline reuptake, strengthening descending pain inhibition.
  • The two mechanisms provide a rational multimodal approach; magnitude of benefit must come from clinical evidence, not mechanism alone.

Composition & dosage

Composition: Gabapentin + Amitriptyline · 300 mg + 10 mg

Dosage form: Tablet

Dosage: As prescribed by the doctor.

How it works

Gabapentin binds the α2δ subunit of voltage-gated calcium channels; amitriptyline inhibits norepinephrine/serotonin reuptake. Together they represent complementary peripheral/central pain-modulation mechanisms.

  1. Gabapentin binds the α2δ subunit of voltage-gated calcium channels
  2. amitriptyline inhibits norepinephrine/serotonin reuptake
  3. Together they represent complementary peripheral/central pain-modulation mechanisms.

Gabapentin and tricyclic antidepressants are both established neuropathic-pain options. Comparative and pathway-sequencing trials support the clinical logic of combining mechanistically different agents when monotherapy is inadequate.

Safety information

  • Dizziness, somnolence, dry mouth, constipation and cognitive effects may occur.
  • Gabapentin exposure is affected by renal function.
  • Avoid abrupt discontinuation and review additive CNS depressant burden.

Review the current approved prescribing information, contraindications, interactions, organ-function considerations, pregnancy/lactation advice and patient-specific risks before prescribing.

Evidence context

Gabapentin and tricyclic antidepressants are both established neuropathic-pain options. Comparative and pathway-sequencing trials support the clinical logic of combining mechanistically different agents when monotherapy is inadequate.

The available trials do not prove that this exact fixed-dose Gabalex-AT formulation is superior to titrated separate agents.